“左手断腕，右手造血”——跨国药企正加速退出低附加值成熟赛道，为新产品结构腾挪空间。近日，国家药监局发布关于注销小儿电解质补给注射液等56个药品注册证书的公告。值得关注的是，在注销的药品名单中，外企产品达到30余个，占比过半，包括辉瑞、诺华、葛兰素史克（GSK）、BI（勃林格殷格翰）等知名药企旗下的部分原研药品。“带量采购压价、专利悬崖冲击、创新药迭代倒逼行业转型升级。”在业内看来，药品撤市是...
Source Link“左手断腕，右手造血”——跨国药企正加速退出低附加值成熟赛道，为新产品结构腾挪空间。近日，国家药监局发布关于注销小儿电解质补给注射液等56个药品注册证书的公告。值得关注的是，在注销的药品名单中，外企产品达到30余个，占比过半，包括辉瑞、诺华、葛兰素史克（GSK）、BI（勃林格殷格翰）等知名药企旗下的部分原研药品。“带量采购压价、专利悬崖冲击、创新药迭代倒逼行业转型升级。”在业内看来，药品撤市是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.